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Abstract
Aujeszky’s disease has been assessed according to the criteria of the Animal Health Law (AHL), in
particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of Aujeszky’s
disease to be listed, Article 9 for the categorisation of Aujeszky’s disease according to disease
prevention and control rules as in Annex IV and Article 8 on the list of animal species related to
Aujeszky’s disease. The assessment has been performed following a methodology composed of
information collection and compilation, expert judgement on each criterion at individual and, if no
consensus was reached before, also at collective level. The output is composed of the categorical
answer, and for the questions where no consensus was reached, the different supporting views are
reported. Details on the methodology used for this assessment are explained in a separate opinion.
According to the assessment performed, Aujeszky’s disease can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL. The disease would comply with the criteria
as in sections 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control
rules referred to in points (d) and (e) of Article 9(1). The animal species to be listed for Aujeszky’s
disease according to Article 8(3) criteria are mainly the species of the family of Suidae as susceptible
species, although almost all mammals can be infected, and Sus scrofa as reservoir species.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and Article 8 within the Animal Health Law (AHL) framework
(EFSA AHAW Panel, 2017).
1.1.1. Interpretation of the Terms of Reference
The interpretation of the ToR is as in section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL)
framework (EFSA AHAW Panel, 2017).
The present document reports the results of assessment on Aujeszky’s disease according to the
criteria of the AHL articles as follows:
• Article 7: Aujeszky’s disease proﬁle and impacts;
• Article 5: eligibility of Aujeszky’s disease to be listed;
• Article 9: categorisation of Aujeszky’s disease according to disease prevention and control rules
as in Annex IV;
• Article 8: list of animal species related to Aujeszky’s disease.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of Aujeszky’s disease according to the Article 7 criteria of
the AHL and related parameters (see table 2 of the opinion on methodology (EFSA AHAW Panel,
2017)), based on the information contained in the fact-sheet as drafted by the selected disease
scientist (see section 2.1 of the scientiﬁc opinion on the ad hoc methodology) and amended by
the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
The primary and only natural host1 of Aujeszky’s disease (AD) is the pig (Sus scrofa), including wild
boar or feral pigs and all genera of the family of Suidae. There are very few reports of detection of
ADV in peccaries (Tayassuidae), the signiﬁcance in this family is difﬁcult to determine due to the
absence of relevant pathological studies (De Castro et al., 2014). However, a large number of other
animal species can be infected naturally or experimentally by the Aujeszky’s disease virus (ADV):
cattle, sheep, goats, dogs, cats, terrestrial wild carnivores and wild mice. Nearly all other mammals are
also thought to be susceptible to the infection, except higher primates, but as dead end hosts
(Spickler, 2017). It is difﬁcult to infect horses and birds; large virus doses are necessary and they must
be injected either intracerebrally, subcutaneously or intramuscularly (Mettenleiter et al., 2012). Higher
primates, including humans, are considered non susceptible to the virus, in spite some clinical cases
reported in humans (see Section 3.1.1.3). Susceptibility to infection depends on several factors
1 Natural hosts are able to survive a productive pseudorabies infection dependent on the age of the animal and the virulence of
the virus.
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including the virulence of the virus strain, the exposure dose, the route of exposure, and the age
(piglets are highly susceptible compared to adult pigs).
Reservoir animal species
The pig (S. scrofa) (including wild boar or feral pigs) is the only species that serves as the reservoir
host (Mettenleiter et al., 2012).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
In a susceptible porcine population, the within-herd prevalence is variable depending on the
structure of the herd, its health management, the density of the pigs, the distance between the
facilities and the biosecurity measures applied by the farmer. In farms with few animals and no
vaccination, serological testing demonstrated a prevalence of the infection below 20%; whereas in
bigger farms, mainly in breeding and ﬁnishing herds, generally the prevalence has been shown to be
much higher and can reach 60% or even 100% (Vannier, 1989). In a more recent survey conducted in
Spanish farms without vaccine interferences, the percentage of seropositive herds was 55% (39–70,
95% CI) in sows and 25% (14–41, 95% CI) in fatteners, while the median within-herd seroprevalence
was 37% (9–87, 95th percentiles) and 100% (7–100, 95th percentiles) in sows and fatteners,
respectively (Lopez-Soria et al., 2009).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
In pigs, morbidity is dependent on the age of the animal. It is not always possible to associate the
within-herd prevalence with case-morbidity, since the clinical expression of the infection in a given herd
depends on multiple factors, and the case-morbidity can be highly variable. In suckling pigs, the case-
morbidity is 100% in most cases. In breeders, the case-morbidity is generally high, but the clinical
expression of the infection can be limited to hyperthermia and anorexia; the rate of abortion is variable
depending on the stage of gestation. In fattening pigs, the case-morbidity might be linked also to the
presence of additional infections; for example, in herds with a high sanitary standard, the clinical
expression of the ADV-infection can be very mild, whereas in herds with the presence of other
infectious agents, such as Mycoplasma, Actinobacillus, Porcine Reproductive and Respiratory Syndrome
Virus, or Swine Inﬂuenza, the frequency of respiratory disorders after the infection by the ADV can be
very high (Vannier, 1987a). In other ADV-infected species the case-morbidity is always 100%.
Mortality
Parameter 3 – Case-fatality rate
In pigs, the case-fatality is strongly dependent on age. Generally, 100% of suckling 15 days old
piglets will die after an ADV infection. In 3 weeks to 1-month-old piglets, the case-fatality decreases to
50%. After weaning as well as in fattening units, the mortality is low, although depending on the
sanitary standard of the herd; if secondary infections are introduced after the ADV infection (see
above), the mortality can increase considerably, reaching 10% (Pol and Le Potier, 2011).
In other species, such as cattle, sheep, goats, cats and dogs, clinical pruritus and encephalitis
characterise the uniformly and systematic fatal infections, i.e. the case fatality is always 100%. It is
important to realise that before the 1970s, AD was reported only for cases of mortality in cattle or
companion animals, such as dogs and cats, whereas the infection in the porcine reservoir population
was not recognised.
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Since 1914, there are several anecdotal reports of AD in humans. Between 1983 and 1986, three
suspected human cases of AD were identiﬁed in Europe. Each of these patients had a history of having
direct contact with cats and other domestic animals. Researchers followed up on the cases and
identiﬁed ADV antibodies through neutralisation and immunoprecipitation assays, 5–15 months after
onset of clinical illness. However, later serological studies were unable to detect ADV antibodies in
occupationally exposed populations (Mravak et al., 1987; Skinner et al., 2001). So, these reports are
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not conclusive; it is generally accepted and has been demonstrated even by self- inoculation that
humans are resistant to natural AD infection (Mettenleiter et al., 2012).
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
This is not applicable as AD is a viral disease and there is no treatment available.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
After an experimental challenge in pigs, the virus can be isolated from nasal swabs up to 12 days,
with virus titres between 103 and 107 50% Tissue Culture Infective Dose (TCID50) per swab (Vannier
et al., 1991). In oropharyngeal swabs, the virus can be detected up to 25 days. Virus is found in
vaginal secretions and foreskin secretions (ejaculate) for up to 12 days and for 2–3 days in milk;
transplacental transmission leads to considerable virus shedding by the sow during abortion and birth
of dead born piglets. Virus is occasionally shed in urine and has been detected in rectal swabs, but not
in faeces, for up to 10 days (Mettenleiter et al., 2012).
Latency is deﬁned as a condition in which viral genomic DNA persists extra-chromosomally, but
infectious virus is not produced. A number of studies have suggested that most, if not all, pigs initially
exposed to ADV can become latently infected carriers. In consequence, virus can be reactivated and
excreted several months or years after the initial infection (Smid et al., 1994). Reactivation can occur
due to stress (transport, handling, temperature, etc.) or hormonal imbalance (gestation, farrowing).
The other susceptible species do not contribute to persistence or latency of the virus, as the fatal
outcome is systematic and occurs few days after the infection.
Environment
Parameter 4 – Length of survival of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low temperature)
ADV is stable under various pH and temperature conditions and is considered resistant in the
environment. The virus survives on hay for 30 days in summer and 46 days in winter. It is stable
between pH 4 and 12, and even at pH values of 2.0 and 13.5, it takes 2–4 h before the virus is
completely inactivated. ADV is relatively resistant to heat. It is inactivated at 60°C in 30–60 min, at
80°C in 3 min and at 100°C within 1 min (Kunev, 1978). Under laboratory conditions, it stays
infectious at 25°C for about 6 weeks, at 15°C for about 9 weeks and at 4°C for about 20 weeks
(Davies and Beran, 1981). In slurry, the virus is thought to remain infectious for about 2 months in
winter and for about 1 month in summer. At high virus doses (106.5 TCID50/mL), infectious virus can
still be detected after 27 weeks at 4°C and 15 weeks at 23°C. In aerated slurry, at pH 9.6 and 44°C,
infectivity disappeared in 8–21 days. In soil, infectious virus was recovered for 5–6 weeks. Virus
dried on sacks and wood persisted for about 10 days in summer and 15 days in winter (Mettenleiter
et al., 2012).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
The virus is spread primarily by direct contact between pigs. Close direct contact is the main
route of transmission of the virus between pigs or wild boar. The mucosae of the nasal and oral
cavities are the main entry points. The virus can also spread via colostrum to suckling piglets (Beran,
1991). Transmission among pigs can also occur during breeding from exposure to contaminated
vaginal mucosae or semen. Sows are often infected during mating or artiﬁcial insemination by
infected boars or infected semen. In the back-yard sector, mainly in the past, boars were transported
from farm to farm for mating (‘rolling/travelling boars’) and, when they were infected, they could
contaminate numerous free holdings (Vannier, 1987a). Under certain climatic circumstances (high
virus load in the air, ventilation, etc.), ADV can be disseminated by the movement of air within
buildings or outside (Vannier, 1989). Cows were often infected and died, when reared close to
infected pigs or outdoors close to the exhaust of air coming from the pens of heavily infected pigs.
Offal of pigs and products containing pig offal (such as head as well as thoracic and abdominal
AHL assessment on Aujeszky’s disease
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(7):4888
viscera) can represent a further transmission route for pigs and other species, if used in feed (see
Section 3.1.4.7).
The relative importance of the different transmission routes depends on the density of pig herds. In
areas with a low density of pig herds, transmission occurs mostly by introduction of infected gilts or
boars, and infected semen used for artiﬁcial insemination. Finishing herds are often contaminated by
the introduction of piglets from infected farrowing units (Vannier, 1987b). In areas with a high density
of pig herds (≥ 0.8 herds per ha), different studies (Donaldson et al., 1983; Christensen et al., 1990)
showed that the virus can be transmitted by air (up to 70 km), and Danish pig farms were shown to
be contaminated through airborne virus from infected German pig farms. In areas with a high density
of pig farms, mainly consisting of farrow-to-ﬁnish herds and ﬁnishing herds, the virus burden can be
very high when several pig farms are infected at the same time and the virus can spread from farms
to farms very quickly.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
A study conducted in 17 herds quarantined for ADV spread to determine the incidence of ADV
within enzootically infected herds detected ADV-infected animals in seven of eight herds that had
more than 400 sows and in two of nine herds that had less than 400 sows. Sample size was
established to detect spread if it was occurring in at least 20% and 22% of 15 and two susceptible
herds, respectively, on annual basis. Annual incidence ranged from 61% to 4.7% (Duffy et al.,
1991).
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
R0 values of 10 and 23 have been suggested in vaccination studies (De Jong and Kimman, 1994;
Bouma et al., 1997).
The speed of transmission of ADV depends on the local structure of the production; in areas with a
high density of infected and susceptible ﬁnishing pigs, and with movements of potentially infected
piglets, the combination of massive aerial excretion of the virus with mixing of animals of different
origins and health status creates favourable conditions for rapid spread of the infection among herds.
In contrast, in areas with a relative low number of pig herds, such as Loire-Atlantique (247 herds
within 6,815 km2) in 1983 and Aquitaine, in the south-west of France, with 5,200 herds (within
41,310 km2) and with 75,000 sows of which 3,900 were infected, the spread of ADV was relatively
limited and slow allowing the implementation of sanitary measures with a very limited vaccination
coverage (Vannier et al., 1997).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
The disease is still present in 13 Member States (MS) and consequently in a signiﬁcant part of
the Union territory. The list of Member States or regions thereof with an approved eradication
programme or with the recognised AD-free status, and having the related additional guaranties
granted for intra Union trade, are listed in Annexes I and II to Commission Decision 2008/185/EC.2
The situation in 2015 is presented in Figure 1 as in point 2.5 of the annual report for bovine and
swine diseases: http://ec.europa.eu/food/sites/food/files/animals/docs/la_bovine_final_report_2015.pdf.
Nevertheless, in many of the countries, the infection, if present, is endemic in the wild boar
population; ADV has been isolated from these animals in Austria, France, Germany, Hungary, Italy,
Slovakia and Spain (Muller et al., 2010). The occurrence of the virus in the wild boar population
seems to be variable according to regions and seems to be associated with the density.
2 Commission Decision of 21 February 2008 on additional guarantees in intra-Community trade of pigs relating to Aujeszky’s
disease and criteria to provide information on this disease. OJ L 59, 4.3.2008, p. 19–30.
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Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
In all MSs where AD is present, the epidemiological situation is variable and the infection can be
considered as endemic.
Risk of introduction
The risk of introduction of AD is mainly linked to the routes of transmission of the ADV. The highest
risk is associated with the trade of live infected piglets, infected breeders (sows and boars), and
infected semen. The movement of infected wild boar across borders can be another possible route of
spread and introduction of the virus into free countries. Similarly the spill-back from still infected wild
boar (present and infected in most nowadays free countries) to pigs, particularly open-air or free-
range raised ones can be a further spread or introduction route.
The number of animals moved is highly variable from one MS to another.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
The diagnosis of AD can be conﬁrmed by isolating the virus from the oropharyngeal ﬂuid, nasal
ﬂuid (swabs) or tonsil swabs from living pigs, or from samples from dead pigs or following the
presentation of clinical signs, such as encephalitis in herbivores or carnivores. For post-mortem
isolation of ADV, samples of brain, tonsil and lung are the preferred specimens. In cattle, infection is
usually characterised by a pruritus, in which case a sample of the corresponding section of the spinal
cord may be required in order to isolate the virus. In latently infected pigs, the trigeminal ganglion is
the most consistent site for virus isolation, although latent virus is usually non-infective unless
reactivated, making it difﬁcult to recover in culture.
Figure 1: Map of EU Member States, Norway and Switzerland free of Aujeszky’s disease (in green), or
where the disease is still present (in orange for countries with an approved control
programme in place, in red for other countries) (source: http://ec.europa.eu/food/sites/
food/files/animals/docs/la_bovine_final_report_2015.pdf)
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The polymerase chain reaction (PCR) can be used to identify ADV genomes in secretions or organ
samples. Many individual laboratories have established effective protocols (OIE, 2012).
Virus neutralisation (VN) has been recognised as the reference method for serology; the VN test is
a prescribed test for the international trade (OIE, 2012).
For general diagnostic purposes, it has been widely replaced by the enzyme-linked immunosorbent
assay (ELISA) because of its suitability for large-scale testing. The tests can be performed on a variety
of matrices (e.g. serum, whole blood, milk, muscular exudates, including these matrices collected on
ﬁlter paper), but the preferred matrix is serum (Pol and Le Potier, 2011). ELISA kits, which are
available commercially, use indirect or competitive techniques for detecting antibodies. They differ in
their mode of preparation of antigen, conjugate or substrate, in the period of incubation and in the
interpretation of the results. Their general advantage is that they enable the rapid processing of large
numbers of samples, they may be automated and the results analysed by computer (OIE, 2012).
Serological tests are carried out only in pigs, as other animals (herbivores and carnivores) die too
quickly to produce antibodies. In free areas where pigs are not vaccinated, an active epidemiological
survey can be carried out using ELISA gB kits. As antibodies can be detected between 7 and 10 days
post-infection, this serological tool can also be used in case of an outbreak suspicion to conﬁrm the
infection of pigs. In areas where pigs are vaccinated with gE-deleted vaccines, the ELISA gE kits allow
the differentiation between infected and vaccinated pigs (DIVA), but to assess the level of immunity
induced by vaccination, gB ELISA kits or viral neutralisation should be used. The sensitivity of ELISA is
generally superior to that of VN test using 1-h neutralisation without complement. Some weak positive
sera are more readily detected by VN tests using 24-h neutralisation, while others are more readily
detectable by ELISA.
A latex agglutination test has also been developed and can be used for screening for antibodies.
Control tools
Parameter 1 – Existence of control tools
All the tools necessary to control and eradicate the disease are available and have been
implemented in the past with satisfying results (see Section 3.1.4).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
See Section 3.1.1.7.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation (milk, growth,
semen, meat, etc.)
There are limited studies about the direct cost of AD. A precise estimation has been done in two
unvaccinated farrow-to-ﬁnish herds (80 sows) taking into account the mortality of piglets, sows and
fattening pigs, as well as the rate of abortion (Godet and Vannier, 1983). The increase of the feed
consumption index was also estimated. In the two respective herds, 132 and 131 piglets died, 3 sows
died in one herd, 5 and 7, respectively, aborted, 2 and 3 fattening pigs died. The feed consumption
index increased by 0.2 in each herd. The cost was calculated in each herd taking into account the
antibiotic additives distributed to cure respiratory disorders and the secondary bacterial infections. The
total cost was 15,051 € (188 € per sow) in one herd and 18,498 € (230 € per sow) in the other one.
These estimates incorporate an inﬂation of 1% per year from 1983 to now.
The losses, however, can be variable from herd to herd. Especially, in the ﬁnishing units, indirect
losses related to a decrease in growth measured by the mean daily growth (MDG) value are strongly
dependent on the herd health status. Under experimental conditions, when the conditions of challenge
are strictly identical, the only variation may be due to the original health status of the pigs, as
described in the following.
Among 41 pigs scattered in seven batches, after challenge with the strain 75V19 at 14–20 weeks of
age and a weight between 70 and 80 kg, the MDG before challenge varied from 767 to 1,015 g; the
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total loss of weight after challenge varied from 7.1 to 15.8 kg; the MDG during 7 days post-challenge
varied from 821 to 2,000 g and during 21 days post-challenge, the MDG varied from 416 to 481 g.
The time to recover the weight they had before challenge was from 13 days to more than 36 days.
None to ﬁve animals died in the different batches (Vannier, 1987a). In these assays, there were
speciﬁc pathogen-free (SPF) pigs, pigs coming from herds with no respiratory disorders and from
conventional herds with chronically respiratory disorders. The differences of performances after
challenge can be explained by the importance of respiratory lesions due to secondary bacterial lung
infections (Vannier, 1987a). Indeed, when SPF pigs are experimentally infected, the pneumonia lesions
induced by the ADV appear in few days after challenge and evolve quickly to cicatrisation. For pigs
coming from herds with chronic respiratory disorders, pneumonic lesions are much more extensive,
with purulent exudate and lesions of pleurisy, pericarditis and peritonitis.
In a study in US conducted in 1990 in a commercial swine herd, preweaning mortality increased
twofold, and subsequently, the number of pigs weaned per litter decreased by 19% (p < 0.005) during
the 5-week epizootic. Also, the number of pigs born alive decreased by 6% during the epizootic. No
signiﬁcant differences in production were observed between the 6-month periods before and after the
epizootic (Parsons et al., 1990).
A more recent Japanese study investigating the effect of ADV infection on productivity in farrow-to-
ﬁnish herds, found a signiﬁcant higher post-weaning mortality in ADV-positive herds (6.84%, 2.29 SD)
compared to negative herds (4.73%, 1.78 SD) and lower marketed pigs per sow (20.1, 2.06 SD),
litters per mated females per year (2.28, 0.15 SD) and farrowing proportion (80.7%, 6.39 SD) than
negative herds (21.7, 2.69 SD; 2.35, 0.12 SD; 85.1%, 7.40 SD, respectively) (Yamane et al., 2015). As
targeted herds volunteered to be part of this study, the authors speciﬁed that this selection bias could
have resulted in the inclusion of herds with higher levels of animal hygiene and those with motivated
owners.
More global studies have been carried out, but it is difﬁcult to compare the different values of direct
and indirect costs induced by AD. In Ohio (USA), estimates ranging from $21 million to nearly
$33 million annually have been proposed for the annual loss experienced by the US swine industry due
to infection with ADV (Bech- Nielsen et al., 1995). An earlier study (Bech- Nielsen et al., 1992)
investigated the effect of pseudorabies in swine farming on both production and economic values. The
study reported an overall loss of 99,700 $ from the beginning of the epizootic to the complete
eradication. The major economic loss was related to suckling pig mortality, which accounted for the
76.5% of the total loss and nursery pig mortality (12.6% of the total loss). Culling and death of sows
accounted for 9.4% of the total losses that occurred from 6 months after the epizootic until
eradication. The remaining 1.2% of the total loss in the same was represented by marketed hog
deaths.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Humans are resistant to natural AD infection, thus there is no impact on human health (see
section 3.1.1.3).
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
The consequences on animal welfare are related to the clinical signs induced by the virus and to
the lesions due to the virus favouring also secondary bacterial infections, complicating the course of
the initial infection. In piglets, the lesions of encephalitis are expressed as severe and painful clinical
signs such as paddling, opisthotonos, convulsions, etc., and are always fatal. In other species than
pigs, the lesions of encephalitis are often expressed as a severe pruritus leading the infected animals
to self-mutilation, in attempt to alleviate the intense pruritus and the pain. Again, death is inevitable.
The old name of AD is ‘mad itch’, which expresses very well the dramatic negative impact of the
infection on animal welfare, as well as the name ‘pseudorabies’, some AD clinical signs being very
similar to the ones of rabies.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
AD can cause signiﬁcant mortality in wild boar (Gortazar et al., 2002). Foxes and other meat-eating
wildlife species can be infected and killed by eating dead infected piglets and aborted foetuses.
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However, it is very difﬁcult to obtain precise statistics in these cases, although there are reports
conﬁrming cases in several endangered carnivores, most recently an Iberian lynx (Masot et al., 2017).
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
Wild boar is a potential reservoir and source of infection for domestic pigs, especially in those
countries where AD eradication programs have been successfully implemented. In Europe, ADV is
present in wild boar in many countries, such as France, Germany, Spain, Italy, Slovenia, Croatia and
the Czech Republic (Mettenleiter et al., 2012). The seroprevalences in these populations range from
4% to 60% at the regional and national levels; these differences seem to be related to the density of
the wild boar population and to the frequency of contacts between these animals. This endemic
infection of wild boar is revealed by serological investigations, while the occurrence of deaths among
hunting dogs can be examined with viral isolation or detection of ADV sequences from the brain of
these dogs. The number of infected hunting dogs varies from region to region, depending on the
habits of hunters to distribute wild boar viscera to their dogs (Pol and Le Potier, 2011). Although AD in
wild boar generally has not impacted the AD-free status of domestic pigs, infected wild boar
populations represent a constant danger for reintroduction of ADV into free regions and countries.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
ADV is not included in any of the lists of agents to be potentially used in bioterrorism.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Currently, there is no European Union (EU) Reference Laboratory for AD. National institutes
responsible for checking the quality of ELISA methods in each MS and for producing and standardising
national reference sera according to the Community reference sera are listed in Annex III to
Commission Decision 2008/185/EC.
Effectiveness
ELISAs used in Europe are accurate in comparison to the blocking and indirect ELISAs, with a
relative sensitivity of 95.12% and 99.37%, respectively, and a relative speciﬁcity of 92.0% and 93.5%,
respectively (Wongwatcharadumrong and Moreno-Lopez, 1990). However, papers reporting precise
sensitivity or speciﬁcity estimates are rare. Most of the tests used currently probably have values up to
96–99% sensitivity and speciﬁcity (Le Potier, 2016).
Feasibility
ELISA kits are used on sera (tested individually or pooled in batches of ﬁve) and for the gB kits,
ﬁlter papers are used to collect blood; the analysis is performed from the elution obtained with an
appropriate buffer. A reference serum-neutralisation test is less frequently used on a routine basis.
Tonsils, brain, lungs, and lymph nodes are generally the matrices used to isolate the virus or to
detect ADV sequences.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
There are inactivated and live attenuated vaccines. In countries with infected pigs, where
eradication of AD is planned, the gene-deleted marker vaccines are the vaccines of choice. The
epidemiological and economical effectiveness of this methodology for regional eradication was
documented in 1991–1994 by an EU-supported project, involving regions in Denmark, Germany and
parts of the Netherlands. The vaccination/test-and-removal programmes, which were carried out in
northern Germany and southern parts of the Netherlands, were the ﬁrst ever area-wide attempts to
eradicate the AD virus from large populations of endemically infected swine herds with the use of
gene-deleted vaccines (Willeberg et al., 1996).
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As most of the European countries eradicated the infection, it is possible that, in case of a crisis at
EU level, it will be difﬁcult to obtain enough vaccine doses from the manufacturers to protect the
endangered population.
Effectiveness
The vaccines are efﬁcient in providing complete protection for young piglets through passive
immunity by vaccinating the dams before farrowing. The vaccines prevent abortion in most cases.
However, in exceptional circumstances, abortion can occur in herds where vaccination with an
inactivated vaccine has been performed in sows. Generally, this occurs when the ‘infectious pressure’ is
very high, the wild AD virus is spreading in a herd with vaccinated sows and unvaccinated fattening
pigs. The virus can reach the fetus despite a strong humoral immunity (Dieuzy et al., 1987).
In fattening pigs, the active immunity induced by vaccination will be more or less efﬁcient
depending on several factors, such as the age of (time since) vaccination, as the passive antibodies
may interfere with the development of an active immunity after vaccination, the number of injections
at the beginning of the fattening period, the type of vaccines (inactivated or live attenuated), the
health status of pigs before vaccination, and infections with or without chronic respiratory disorders.
The clinical protection of the fattening pigs can be measured by objective criteria such as index DG,
which is the difference in mean relative daily weight gain (MRDG) during the 7 days post-challenge
period between vaccinated and control groups (Vannier et al., 1995). Such criteria are used by the
European Pharmacopeia to provide the rules for marketing authorisation (European Pharmacopoeia,
2013). When fattening pigs are immunised, the difference of the MRDG values between the control
and vaccinated groups 7 days after challenge should not be less than 1.5 kg, with no vaccinated pigs
dying after challenge. To measure the clinical protection induced by the passive immunity from
vaccinating the dams, their 6–10 days old piglets are challenged: 100% of the control piglets should
die after challenge and 80% or more of the piglets from the vaccinated sows should survive to the
challenge.
However, vaccination of pigs does not prevent viral shedding and latency. Vaccination shortens the
period of viral excretion after infection and decreases the quantity of virus excreted.
Assays showed that a double vaccination of seronegative pigs reduces transmission of ADV among
vaccinated pigs compared to the transmission among the unvaccinated pigs (De Jong and Kimman,
1994). The R0 was reduced from 10 to 0.5. However, when a single vaccination was performed at
10 weeks of age in pigs with maternal antibodies, R0 was equal to 23, whereas, when a double
vaccination was carried out with presence of maternal antibodies at 10 and 14 weeks of age, the R0
decreased to 0.6 (Bouma et al., 1997). No vaccines can prevent latent infection and subsequent
reactivation and shedding of virulent ﬁeld virus (Mettenleiter et al., 2012).
Parameter 3 – Duration of protection
Passive protection: The duration of the persistence of the passive antibodies depends on
numerous factors: the number of vaccine injections given to the dams – also related to the age of the
sows – the type of vaccine used, the quantity of colostrum taken in by the neonatal piglet, its rank in
the litter, the temperature of the environment of the piglet at the moment of birth. With the most
efﬁcient vaccines given to the sows, passive antibodies can be detected in the serum of 17 weeks old
pigs (Vannier, 1985). However, in most cases, passive antibodies are detected in the serum of
fattening pigs until 12–14 weeks of age.
Active protection: Whatever the type of vaccine (live-attenuated or inactivated), the active
immunity does not provide a good protection beyond 6 months after vaccination; therefore, booster
injections should be carried out every 6 months.
Feasibility
Most vaccines are administered by the intramuscular route. This is done easily under practical
conditions, when the pigs are reared in closed buildings. The implementation of a systematic
vaccination programme is more difﬁcult when pigs are reared on free range, as occurs in some regions
within the EU, such as Corsica and Sardinia.
To prevent local reaction, few vaccines have got a marketing authorisation for the intradermal route
(Vannier and Cariolet, 1989).
3.1.4.3. Article 7(d)(iii) Medical treatments
This is not applicable (see Section 3.1.1.4).
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3.1.4.4. Article 7(d)(iv) Biosecurity measures
In most cases, the classical biosecurity measures (control of health status of purchased pigs,
quarantine, fencing, shower or change of clothes for staff and visitors, water-bath for boots and truck
wheels, etc.) are efﬁcient to prevent the introduction of the virus into a herd. These measures are
currently applied in most herds in countries with a developed porcine production and industrial pig
farms. Nevertheless, in some MSs, pig farms with no protection and no implementation of biosecurity
measures may still be found.
In areas with a high density of infected pig herds, airborne transmission of the virus is possible (see
above); accordingly, classical biosecurity measures are inefﬁcient in those cases. To prevent the
introduction of the virus into nucleus herds or semen collection centres, ﬁltration of the air entering
into the pig buildings was implemented in these high-level health-status herds (Dutertre et al., 1995).
Depending on the level of risk, F9 ﬁltration (99% of efﬁciency on particles ≥ 1 lm) or H12 ﬁltration
(99.5% efﬁcient on particles whatever their size) was implemented in those herds.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
In most countries, especially when the initial prevalence of the infection is variable from region to
region or relatively high (see above), control and eradication programmes were implemented following
different steps. Indeed, a programme of control against AD can be successful only if a comprehensive
set of measures is carried out.
3.1.4.6. Article 7(d)(vi) Killing of animals
In AD eradication programmes, depending on the epidemiological situations, three different speciﬁc
measures were carried out: total slaughter, partial slaughter (part of the herd) after a test-and-culling
procedure or a systematic DIVA vaccination programme with backup serological examinations in
fattening pigs and breeders long enough to ensure that the herds do not pose any epidemiological risk
to the neighbourhood; in those herds, when the regular culling of sows inside each herd allowed an
elimination of infected breeders, a test-and-slaughter procedure could be implemented for breeders to
accelerate the cleaning of the herds. Infected breeders were then sent to slaughter.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
There is no restriction on the consumption of carcasses, as ADV is not zoonotic. Moreover, the virus
is rarely isolated from the blood and the meat. Nevertheless, offal (head as well as thoracic and
abdominal viscera) of pigs and products containing pig offal represent an epidemiological risk for pigs
and other species, if used in feed. For that reason, those products cannot be used or introduced in
free regions or countries from provisionally free countries or zones or from infected countries or zones,
if they do not come from an ofﬁcially free establishment or if they have not been processed to ensure
the destruction of the AD virus (OIE, 2016).
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
It is often thought that sanitary measures are much more costly than vaccination preventive
measures. The AD eradication programmes costs are proving the opposite. However, very few studies
have been done on that subject. Precise costs were established in French regions with sanitary
programmes including total or partial slaughter of herds and, in exceptional cases, vaccination of
limited herds with test-and-slaughter of infected sows and boar. For example, in Loire-Atlantique,
which included 247 herds, the programme began in 1983. Over 3 years, the costs of the eradication
programme approximated 180,000 €, including everything: blood sampling, laboratory analyses,
vaccines, compensation, mortality, staff and travel expenses. The programme included 10,000 sows,
making the cost per sow per year of 6 €. Farmers paid a levy of 4.31 € per sow per year. Local or
regional authorities covered the remaining costs. This calculation took into account an inﬂation of 1%
per year. The veterinary authorities paid only part of the staff and supplied the kits for the serological
tests. In the region of Aquitaine (1984), where vaccination was prohibited after 2 years of campaign,
80,000 blood samples were drawn from 5,200 herds. Out of these samples, 3,900 sows were infected
and 4,200 have been slaughtered in the ﬁrst stage of the eradication campaign. Here, the total cost
had been 1,800,000 € for 75,000 sows in a period of 4 years that means 24 € per sow or 6 € again
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per sow per year. The levy paid by the farmers for the ﬁrst and second year was around 2 € per sow
per year (a little more the next 2 years), the remainder was paid by local, regional and national
authorities (Vannier et al., 1997).
The costs were much higher in regions with a vaccination programme. Indeed, in Brittany, in a ﬁrst
step, the pig producers decided to implement only a systematic vaccination programme without any
other general or speciﬁc measures. From 1987 to 1992, during 5 years, in each herd, sows, boar and
fattening pigs were systematically vaccinated. At the end of this period, the campaign was a failure as
the prevalence of the infection in the region was the same as before the programme implementation.
So, in 1994, the producers accepted to change of strategy: to maintain a systematic vaccination, but
associated to other general and speciﬁc measures as described before. Therefore, the cost of the
programme had to include the cost of vaccination in each animal (breeders and fattening pigs) every
6 months cumulated on the number of years to reach the eradication plus the cost of blood sampling
and testing and the costs related to the anticipated culling of infected breeders. In regions with
sanitary programmes, the eradication can be reached in 3–4 years, whereas, in regions with medical
prophylaxis, eradication is rarely reached before 10–15 years or more.
According to Willeberg et al. (1996), a computerised economical model to estimate the effects of
ADV infection at the herd and area levels has been developed as part of the EU project on AD
vaccination in Germany and the Netherlands, 1991–1994. The analytical structure consisted of a basic
epidemiological model linked to an economic estimation framework. The economic model predictions
allow priorities to be given to alternative control strategies. Mass vaccination of all pigs in regions with
endemically infected herds followed by test-and-removal of seropositive animals is the most cost-
effective way to control the spread of ADV within the swine population. Other possible control
strategies, such as intensive vaccination or complete test-and-removal, all had higher overall costs,
either because of the less efﬁcient production or because of the high costs of straight test-and-removal.
As some regions or countries eradicated AD, indirect costs are related to the limitations of trade of
live animals between infected regions or countries and ofﬁcially-free ones. As example, the estimated
cost of AD per year in the US was over 30,000,000 $ (APHIS, 1999).
A probabilistic risk assessment and cost-effectiveness analysis using Monte Carlo simulation was
developed for the Guijuelo region in Spain to assess the most safety strategy for moving the animals
and avoiding the risk of introducing ADV-infected pigs in free or low-prevalence areas and the related
cost of the strategy (Martinez-Lopez et al., 2009). The overall cost of the AD programme for Guijuelo
was 649,398 € per year, due to the costs of the tests (885 €), of the veterinarians (631,071 €) and of
vaccination (16,609 €); the reference strategy consisted in testing the animals 15 and 45–170 days
prior to the movement for breeding pigs and fattening pigs, respectively, using a sample size sufﬁcient
to detect a 2% prevalence with 95% CI in breeding farms and a 5% prevalence with 95% CI in
fattening farms. According to the authors, the risk of ADV introduction could be reduced by 89%
testing fattening farms 15 days prior to animal movement without additional cost, and by 99%
increasing the sample size to detect a 1% seroprevalence, although the cost would increase by 91%.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
To eradicate AD, stamping out in the farm of the infected animals was never carried out, thus,
there is no problem of social acceptance of the eradication programmes.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
There is no welfare impact beyond normal practice for the control measures adopted in domestic
pigs, as the infected animals are sent to slaughterhouses.
Parameter 2 – Wildlife depopulation as control measure
There are no possible control measures of AD on wildlife, except to set up fences to prevent the
mating of sows in oestrus by wild boar. These measures have no real impact on the welfare of wildlife.
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3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Other types of impact on environmental compartments such as soil, water, feed and manure linked
to the use and potential residuals of biocides or medical drugs is not relevant, since no medical
treatment is applied.
Biodiversity
Parameter 2 – Mortality in wild species
The impact that AD may have on biodiversity can be linked to the potentially increased mortality in
meat-eating wildlife including endangered species.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about AD (Table 1). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 11. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 1: Outcome of the expert judgement on the Article 5 criteria for Aujeszky’s disease
Criteria to be met by the disease: According to AHL, a disease shall be included in the list
referred to in point (b) of paragraph 1 of Article 5 if it has been assessed in accordance with
Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease: In addition to the criteria set out above at point A(i)-A(v),
the disease needs to fulﬁl at least one of the following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or
not relevant to judge.
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3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Table 2). The proportion of Y, N or na answers are reported, followed by
the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• ADV can cause deaths in endangered carnivores, e.g. bear, lynx (Masot et al., 2017). Few deaths
in already rare animal species may have an impact on the biodiversity, at least in local situations.
Supporting No:
• ADV currently still exists in wildlife populations (including wild boar) in many MSs, even in
those that have eradicated ADV in domestic pigs, without any apparent serious negative
impact on the environment or biodiversity.
3.2.2. Outcome of the assessment of Aujeszky’s disease according to criteria of
Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 1, AD complies
with all criteria of the ﬁrst set and with two criteria of the second set; therefore, it is considered
eligible to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about AD disease (Tables 3, 4, 5, 6 and 7). The expert judgement
was based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement. The minimum number of judges in the
judgement was ten. The expert judgement was conducted as described in the methodological opinion
(EFSA AHAW Panel, 2017). For details on the interpretation of the questions, see Appendix B of the
methodological opinion (EFSA AHAW Panel, 2017).
Table 2: Outcome of the expert judgement related to criterion 5 B(v)
Question Final outcome
Response
Y (%) N (%) na (%)
B(v) Disease has or could have a signiﬁcant negative impact
on the environment, including biodiversity, of the Union
NC 55 45 0
NC: non-consensus; Number of judges: 11.
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Table 4: Outcome of the expert judgement related to the criteria of section 2 of Annex IV
(category B of Article 9) for Aujeszky’s disease
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free of
the disease
Y
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease: In addition to the criteria set out above at point 1–2.4, the
disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
NC
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 3: Outcome of the expert judgement related to the criteria of section 1 of Annex IV
(category A of Article 9) for Aujeszky’s disease
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional cases
(irregular introductions) OR present in only in a very limited part of the territory of the Union
N
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept animals
of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
At least one criterion to be met by the disease: In addition to the criteria set out above at point 1–2.4, the
disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
NC
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 8, 9 and
10). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting
views for each answer.
Table 6: Outcome of the expert judgement related to the criteria of section 4 of Annex IV
(category D of Article 9) for Aujeszky’s disease
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of section 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 7: Outcome of the expert judgement related to the criteria of section 5 of Annex IV
(category E of Article 9) for Aujeszky’s disease
Diseases in category E need to fulﬁl criteria of section 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
Y
Colour code: green = consensus (Yes/No).
Table 5: Outcome of the expert judgement related to the criteria of section 3 of Annex IV
(category C of Article 9) for Aujeszky’s disease
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease: In addition to the criteria set out above at point 1–2.4, the
disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
NC
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Reasoning supporting the judgement
Supporting Yes for 4 (cat.A,B):
• Currently, there is an economic impact in more than two countries and this can be considered
signiﬁcant for the Union.
• All types of pig production and even other animal species of signiﬁcant importance (e.g. cattle)
can be potentially affected, if the disease would be introduced.
Supporting Yes for 4 (cat.C):
• There may be high mortality in piglets.
• In countries where the disease is still present, in breeding and ﬁnishing herds, the herd
seroprevalence is generally high and can reach 60–100%.
Supporting No for 4 (cat.A,B,C):
• Currently, countries with a pig industry of relevance to the EU economy have AD eradicated.
Countries with endemic ADV have a pig industry of lesser importance to the economy of the
Union, and in the presence of vaccination currently does not even have a reported impact on
the economy of the individual MS so therefore it cannot have an impact on the economy of the
Union as a whole. Furthermore, the limited studies on the impact of ADV on production are
mainly related to the situation in the 1970s/1980s when the pig industry was different than
nowadays.
Reasoning supporting the judgement
Supporting Yes:
• In a population with endemic ADV (including wild pig or wild boar populations), the clinical
manifestation of the disease is only seen if na€ıve animals are exposed and the nature of the
manifestation then depends on a multiplicity of factors. In addition, the data reported on
seroprevalence does not seem to indicate that a large number of wild boar would be affected
with severe clinical signs. Therefore, na€ıve wildlife can have clinical symptoms and piglets from
na€ıve sows high mortality but little or no evidence is available.
• Severe signs such as encephalitis and itching (mad itch) in affected animals impact animal
welfare.
Table 8: Outcome of the expert judgement related to criterion 4 of Article 9
Question*
Final
outcome
Response
Y (%) N (%)
na
(%)
4
(cat.A,B)
The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
NC 64 18 0
4 (cat.C) The disease has a signiﬁcant impact on the economy of the
Union, mainly related to its direct impact on certain types of
animal production systems
NC 18
NC: non-consensus; Number of judges: 11.
*: At the time of the collective judgement the assessment of the current impact (CI) considering the control measures in place
was considered.
Table 9: Outcome of the expert judgement related to criterion 5(b) of Article 9
Question* Final outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare,
by causing suffering of large numbers of animals
NC 82 18 0
NC: non-consensus; Number of judges: 10.
*: At the time of the collective judgement the assessment of the current impact considering the control measures in place was
considered.
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Supporting No:
• Currently, many MSs have an infrequent occurrence.
• It is not known if a large number of animals could potentially be affected.
Reasoning supporting the judgement
Supporting Yes:
• Endangered carnivores (e.g. bear, lynx) can potentially be affected, although not currently.
Few deaths in already rare animal species may have an impact on the biodiversity.
Supporting No:
• The disease does not appear currently to threaten the survival of largely abundant species
such as wild boar or even endangered species at a level leading to a signiﬁcant impact.
3.3.2. Outcome of the assessment of criteria in Annex IV for Aujeszky’s disease
for the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for AD for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 11.
Table 10: Outcome of the expert judgement related to criterion 5(c) of Article 9
Question*
Final
outcome
Response
Y (%) N (%) na (%)
5(c) The disease has a signiﬁcant impact on the environment, due to the
direct impact of the disease OR due to the measures taken to
control it
NC 40 60 0
NC: non-consensus; Number of judges: 10.
*: At the time of the collective judgement the assessment of the current impact considering the control measures in place was
considered.
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According to the assessment here performed, AD complies with the following criteria of the sections
1–5 of Annex IV of the AHL for the application of the disease prevention and control rules referred to
in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set (1,
2.1–2.4) and according to the assessment AD complies with criteria 2.2, 2.3 and 2.4 but not
with 1 and 2.1. To be eligible for category A, a disease needs to comply additionally with one
of the criteria of the second set (3, 4, 5a–d) and AD does not comply with criteria 3, 5a and
5d, and this assessment is inconclusive on compliance with criteria 4, 5b and 5c.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set (1,
2.1–2.4) and according to the assessment AD complies with criteria 1, 2.1, 2.2 and 2.3 but
not with 2.4 because the disease is associated with high mortality instead of low mortality.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and AD does not comply with criteria 3, 5a and 5d and this
assessment is inconclusive on compliance with criteria 4, 5b and 5c.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set (1,
2.1–2.4) and according to the assessment AD complies with criteria 1, 2.1, 2.2 and 2.3 but
not with 2.4 because the disease is associated with high mortality instead of low mortality.
To be eligible for category C, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and AD does not comply with criteria 3, 5a and 5d and this
assessment is inconclusive on compliance with criteria 4, 5b and 5c.
4) To be assigned to category D, a disease needs to comply with criteria of section 1, 2, 3 or 5 of
Annex IV of the AHL and with the speciﬁc criterion D of section 4, which AD complies with.
5) To be assigned to category E, a disease needs to comply with criteria of section 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, which AD complies with.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
AD. The Article 8(3) criteria are about animal species to be listed, as it reads below:
Table 11: Outcome of the assessment of criteria in Annex IV for Aujeszky’s disease for the purpose
of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1 set of criteria 2 set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.3 According to the
mapping, as presented in table 5, section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for Aujeszky’s disease according to the
criteria of Article 8(3) of the AHL are as displayed in Table 12.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of the
AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, AD complies with all criteria of the ﬁrst set and
with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, AD meets the criteria as in sections 4 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for AD according to Article 8(3) of the AHL are, as susceptible species, the species
belonging to the family of Suidae and nearly all other mammals as dead end hosts (except
higher primates), and Sus scrofa as reservoir species, as reported in Table 12 in Section 3.4 of
the present document.
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Abbreviations
AD Aujeszky’s disease
ADV Aujeszky’s disease virus
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
ELISA enzyme-linked immunosorbent assay
ICBA Individual and Collective Behavioural Aggregation
MDG mean daily growth
MRDG mean relative daily weight gain
MS Member State
PCR polymerase chain reaction
AHL assessment on Aujeszky’s disease
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SPF speciﬁc pathogen-free
TCID50 50% Tissue Culture Infective Dose
ToR Terms of Reference
VN virus neutralisation
AHL assessment on Aujeszky’s disease
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